Which has higher valuation & earnings, ENOV or BLCO?

Bausch + Lomb has higher revenue and earnings than Enovis. Bausch + Lomb is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.69 -$1.18B -$19.88 N/A Bausch + Lomb $5.10B 1.12 -$360M -$0.62 N/A

Is ENOV or BLCO more profitable?

Bausch + Lomb has a net margin of -4.21% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media refer more to ENOV or BLCO?

In the previous week, Enovis had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for Enovis and 2 mentions for Bausch + Lomb. Enovis' average media sentiment score of 0.75 beat Bausch + Lomb's score of 0.58 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ENOV or LIVN?

LivaNova has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.69 -$1.18B -$19.88 N/A LivaNova $1.39B 3.16 -$242.47M $1.95 40.95

Is ENOV or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% LivaNova 7.48% 16.48% 7.59%

Which has preferable earnings and valuation, MMED or ENOV?

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $3.10B 1.51 -$190.97M -$0.68 N/A Enovis $2.25B 0.69 -$1.18B -$19.88 N/A

Is MMED or ENOV more profitable?

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat MiniMed Group's return on equity. Company Net Margins Return on Equity Return on Assets MiniMed Group N/A N/A N/A Enovis -49.92% 10.32% 4.57%

Does the media favor MMED or ENOV?

In the previous week, MiniMed Group had 10 more articles in the media than Enovis. MarketBeat recorded 15 mentions for MiniMed Group and 5 mentions for Enovis. Enovis' average media sentiment score of 0.75 beat MiniMed Group's score of 0.07 indicating that Enovis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enovis 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NVST or ENOV?

Envista has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Envista $2.72B 1.61 $47M $0.41 65.70 Enovis $2.25B 0.69 -$1.18B -$19.88 N/A

Is NVST or ENOV more profitable?

Envista has a net margin of 2.41% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets Envista 2.41% 7.11% 3.91% Enovis -49.92% 10.32% 4.57%

Does the media prefer IRTC or ENOV?

In the previous week, iRhythm Technologies had 6 more articles in the media than Enovis. MarketBeat recorded 11 mentions for iRhythm Technologies and 5 mentions for Enovis. Enovis' average media sentiment score of 0.75 beat iRhythm Technologies' score of 0.40 indicating that Enovis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Enovis 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enovis (ENOV) Competitors

$27.05 +0.21 (+0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$27.09 +0.04 (+0.16%)

As of 04:49 PM Eastern

Compare

ENOV vs. BLCO, LIVN, MMED, NVST, and IRTC

Should you buy Enovis stock or one of its competitors? MarketBeat compares Enovis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enovis include Bausch + Lomb (BLCO), LivaNova (LIVN), MiniMed Group (MMED), Envista (NVST), and iRhythm Technologies (IRTC). These companies are all part of the "medical equipment" industry.

How does Enovis compare to Bausch + Lomb?

Enovis (NYSE:ENOV) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Bausch + Lomb has higher revenue and earnings than Enovis. Bausch + Lomb is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.69	-$1.18B	-$19.88	N/A
Bausch + Lomb	$5.10B	1.12	-$360M	-$0.62	N/A

Enovis has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Bausch + Lomb has a net margin of -4.21% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, Enovis had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for Enovis and 2 mentions for Bausch + Lomb. Enovis' average media sentiment score of 0.75 beat Bausch + Lomb's score of 0.58 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Enovis shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.9% of Enovis shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Enovis presently has a consensus price target of $41.71, suggesting a potential upside of 54.22%. Bausch + Lomb has a consensus price target of $18.00, suggesting a potential upside of 12.60%. Given Enovis' stronger consensus rating and higher possible upside, equities analysts plainly believe Enovis is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Enovis beats Bausch + Lomb on 12 of the 17 factors compared between the two stocks.

How does Enovis compare to LivaNova?

Enovis (NYSE:ENOV) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Enovis presently has a consensus target price of $41.71, indicating a potential upside of 54.22%. LivaNova has a consensus target price of $81.38, indicating a potential upside of 1.91%. Given Enovis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Enovis is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

98.5% of Enovis shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Enovis has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
LivaNova	7.48%	16.48%	7.59%

LivaNova has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.69	-$1.18B	-$19.88	N/A
LivaNova	$1.39B	3.16	-$242.47M	$1.95	40.95

In the previous week, Enovis had 5 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Enovis and 0 mentions for LivaNova. Enovis' average media sentiment score of 0.75 beat LivaNova's score of 0.24 indicating that Enovis is being referred to more favorably in the media.

Company	Overall Sentiment
Enovis	Positive
LivaNova	Neutral

Summary

Enovis beats LivaNova on 10 of the 17 factors compared between the two stocks.

How does Enovis compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Enovis (NYSE:ENOV) are both medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

MiniMed Group currently has a consensus price target of $21.33, suggesting a potential upside of 27.74%. Enovis has a consensus price target of $41.71, suggesting a potential upside of 54.22%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.51	-$190.97M	-$0.68	N/A
Enovis	$2.25B	0.69	-$1.18B	-$19.88	N/A

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Enovis	-49.92%	10.32%	4.57%

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 2.2% of MiniMed Group shares are held by insiders. Comparatively, 2.9% of Enovis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MiniMed Group had 10 more articles in the media than Enovis. MarketBeat recorded 15 mentions for MiniMed Group and 5 mentions for Enovis. Enovis' average media sentiment score of 0.75 beat MiniMed Group's score of 0.07 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiniMed Group and Enovis tied by winning 8 of the 16 factors compared between the two stocks.

How does Enovis compare to Envista?

Envista (NYSE:NVST) and Enovis (NYSE:ENOV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Envista has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.61	$47M	$0.41	65.70
Enovis	$2.25B	0.69	-$1.18B	-$19.88	N/A

Envista presently has a consensus target price of $28.54, suggesting a potential upside of 5.95%. Enovis has a consensus target price of $41.71, suggesting a potential upside of 54.22%. Given Enovis' stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

Envista has a net margin of 2.41% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Enovis	-49.92%	10.32%	4.57%

98.5% of Enovis shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 2.9% of Enovis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Enovis had 5 more articles in the media than Envista. MarketBeat recorded 5 mentions for Enovis and 0 mentions for Envista. Enovis' average media sentiment score of 0.75 beat Envista's score of 0.00 indicating that Enovis is being referred to more favorably in the news media.

Company	Overall Sentiment
Envista	Neutral
Enovis	Positive

Envista has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Enovis has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Summary

Enovis beats Envista on 11 of the 17 factors compared between the two stocks.

How does Enovis compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Enovis (NYSE:ENOV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

iRhythm Technologies has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Enovis has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

In the previous week, iRhythm Technologies had 6 more articles in the media than Enovis. MarketBeat recorded 11 mentions for iRhythm Technologies and 5 mentions for Enovis. Enovis' average media sentiment score of 0.75 beat iRhythm Technologies' score of 0.40 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Enovis shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

iRhythm Technologies has a net margin of -3.53% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Enovis	-49.92%	10.32%	4.57%

iRhythm Technologies currently has a consensus target price of $186.62, suggesting a potential upside of 71.21%. Enovis has a consensus target price of $41.71, suggesting a potential upside of 54.22%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe iRhythm Technologies is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

iRhythm Technologies has higher earnings, but lower revenue than Enovis. iRhythm Technologies is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$787.85M	4.55	-$44.55M	-$0.86	N/A
Enovis	$2.25B	0.69	-$1.18B	-$19.88	N/A

Summary

iRhythm Technologies beats Enovis on 9 of the 17 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	MEDICAL INFO SYS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.56B	$1.77B	$6.81B	$23.42B
Dividend Yield	N/A	N/A	2.67%	4.15%
P/E Ratio	-1.36	75.28	27.00	30.95
Price / Sales	0.69	17.73	516.15	20.00
Price / Cash	1.01	27.29	26.68	18.81
Price / Book	1.04	5.36	10.67	4.76
Net Income	-$1.18B	-$54.76M	$3.60B	$1.07B
7 Day Performance	9.35%	-1.76%	-0.37%	0.63%
1 Month Performance	23.21%	0.04%	1.80%	1.56%
1 Year Performance	2.63%	-2.09%	25.50%	17.80%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	3.9381 of 5 stars	$27.05 +0.8%	$41.71 +54.2%	+2.1%	$1.56B	$2.25B	N/A	7,802	Gap Down
BLCO Bausch + Lomb	3.8881 of 5 stars	$16.25 +0.1%	$18.00 +10.8%	+14.9%	$5.80B	$5.10B	N/A	13,000	News Coverage
LIVN LivaNova	1.6526 of 5 stars	$82.98 +0.5%	$80.75 -2.7%	+88.7%	$4.54B	$1.39B	42.55	3,300
MMED MiniMed Group	2.5947 of 5 stars	$16.10 +5.3%	$21.33 +32.5%	N/A	$4.52B	$3.10B	N/A	8,000	News Coverage Analyst Upgrade
NVST Envista	2.4756 of 5 stars	$26.23 +1.2%	$28.54 +8.8%	+36.5%	$4.22B	$2.72B	63.97	12,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors

ENOV vs. BLCO, LIVN, MMED, NVST, and IRTC

How does Enovis compare to Bausch + Lomb?

Summary

How does Enovis compare to LivaNova?

Summary

How does Enovis compare to MiniMed Group?

Summary

How does Enovis compare to Envista?

Summary

How does Enovis compare to iRhythm Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enovis (ENOV) Competitors

ENOV vs. BLCO, LIVN, MMED, NVST, and IRTC

How does Enovis compare to Bausch + Lomb?

Which has higher valuation & earnings, ENOV or BLCO?

Which has more risk and volatility, ENOV or BLCO?

Is ENOV or BLCO more profitable?

Does the media refer more to ENOV or BLCO?

Do institutionals and insiders have more ownership in ENOV or BLCO?

Do analysts rate ENOV or BLCO?

Summary

How does Enovis compare to LivaNova?

Do analysts rate ENOV or LIVN?

Do institutionals & insiders hold more shares of ENOV or LIVN?

Which has more volatility & risk, ENOV or LIVN?

Is ENOV or LIVN more profitable?

Which has stronger earnings & valuation, ENOV or LIVN?

Does the media prefer ENOV or LIVN?

Summary

How does Enovis compare to MiniMed Group?

Do analysts recommend MMED or ENOV?

Which has preferable earnings and valuation, MMED or ENOV?

Is MMED or ENOV more profitable?

Do institutionals and insiders have more ownership in MMED or ENOV?

Does the media favor MMED or ENOV?

Summary

How does Enovis compare to Envista?

Which has stronger valuation and earnings, NVST or ENOV?

Do analysts recommend NVST or ENOV?

Is NVST or ENOV more profitable?

Do institutionals & insiders have more ownership in NVST or ENOV?

Does the media favor NVST or ENOV?

Which has more risk and volatility, NVST or ENOV?

Summary

How does Enovis compare to iRhythm Technologies?

Which has more risk & volatility, IRTC or ENOV?

Does the media prefer IRTC or ENOV?

Do insiders & institutionals hold more shares of IRTC or ENOV?

Is IRTC or ENOV more profitable?

Do analysts recommend IRTC or ENOV?

Which has stronger earnings & valuation, IRTC or ENOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools